Company Overview and News

 
KLCI seen trending sideways, immediate support at 1,786

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI is expected to trend sideways today with immediate support at 1,786.
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
George Kent, Axiata, Astro, Bumi Armada, United Malacca, Poh Huat, MAHB, Apex Equity, Poh Kong, Hai-O and Eversendai

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
Lower gold prices eat into Poh Kong’s 4Q net profit

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The drop in gold prices has weighed on Poh Kong Holdings Bhd’s net profit for the fourth quarter ended July 31, 2018 (4QFY18).
5080 BSMAF 1818

1
RAM upgrades retail sector outlook to stable ahead of SST rollout

2018-07-27 theedgemarkets - 1
KUALA LUMPUR (July 27): RAM Rating Services Bhd has upgraded the outlook of the retail sector to stable from negative, ahead of the implementation of the sales and services tax (SST) in September, which is expected to keep the sector in a highly competitive market.
5080

4
Poh Kong 3Q net profit falls 42% on gold price fluctuation

2018-06-13 theedgemarkets
KUALA LUMPUR: Poh Kong Holdings Bhd’s third-quarter net profit fell 41.79% to RM4.31 million, from RM7.4 million a year earlier, due to fluctuation in gold prices.
5080 BSMAF 1818

1
KLCI likely to continue struggling, BN-linked Sarawak stocks seen in focus

2018-06-12 theedgemarkets
KUALA LUMPUR (June 13): The FBM KLCI is likely to struggle to make any gains today, as investors may take a wait and see approach until after the Hari Raya Aidilfitri holidays starting Friday.
5080 3204 1201 7079

5
BAuto, Poh Kong, Tiger Synergy, Comintel, PUC, AppAsia, Sumatec and George Kent

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): Based on corporate announcements and news flow today, companies in focus on Wednesday (June 13) may include: Bermaz Auto Bhd, Poh Kong Holdings Bhd, Tiger Synergy Bhd, Comintel Corp Bhd, PUC Bhd, AppAsia Bhd, Sumatec Resources Bhd and George Kent (M) Bhd.
5080 3204 1201 BSMAF 1818 7079

4
Poh Kong 3Q net profit falls 42% on gold price fluctuation

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): Poh Kong Holdings Bhd’s third quarter net profit fell 41.79% to RM4.31 million, from RM7.4 million a year earlier, due to fluctuation in gold prices.
5080 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...